Renaissance Capital logo

Tenaya Therapeutics Priced, Nasdaq: TNYA

Preclinical biotech developing multiple therapies to treat heart disease.

Industry: Health Care

Latest Trade: $19.85 0.00 (0.0%)

First Day Return: +2.3%

Return from IPO: +32.3%

Industry: Health Care

We are a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, the leading cause of death in the world, and in doing so improve and extend the lives of millions of individuals and families. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with both rare and highly prevalent forms of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and University of Texas Southwestern Medical Center (UTSW), we are developing therapies through scientific advancements in three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. While our Gene Therapy and Cellular Regeneration platforms focus on the use of viral vectors for drug delivery, our Precision Medicine platform enables us to identify promising targets and product candidates in a modality-agnostic manner, including gene therapies, small molecules, and biologics.
more less
IPO News for Tenaya Therapeutics
more
IPO Data
IPO File Date 07/09/2021
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 12.0
Deal Size ($mm) $180
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/29/2021
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 12.0
Deal Size ($mm) $180
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2016
Employees 85
Website www.tenayatherapeutics.com